drugset
drugset / Trial / NCT04989010

Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors

NCT04989010 ↗

Unknown 20 enrolled Wuxi No. 4 People's Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled anti-CLDN18.2 mAbs (89Zr-NY005) PET imaging in patients with CLDN18.2 positive solid tumors.

Timeline

Start
2021-08-01
Primary completion
2022-08-31
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 89Zr-NY005 Monoclonal antibody 10 mg Intravenous

Indications

cancer